Periodic reinterpretation of genetic sequencing results presents a challenge for developing transparent and systematic coverage and reimbursement policies.
David L. Veenstra, PharmD, PhD
Advertisement
Articles by David L. Veenstra, PharmD, PhD
This study critically assessed the published clinical and economic evidence supporting oncology orphan drugs marketed in the United States.
Advertisement
Latest Updated Articles
- Reimbursement for Genetic Variant Reinterpretation: Five Questions Payers Should Ask
Published: October 14th 2021 | Updated:
- Genetic Testing and Pharmacogenomics: Issues for Determining the Impact to Healthcare Delivery and Costs
Published: July 1st 2004 | Updated:
- Managed Care in the Genomics Era: Assessing the Cost Effectiveness of Genetic Tests
Published: July 1st 2003 | Updated:
- Toward Evidence-based Assessment for Coverage and Reimbursement of Laboratory-based Diagnostic and Genetic Tests
Published: April 1st 2006 | Updated:
- Systematic Review of Comparative Effectiveness Data for Oncology Orphan Drugs
Published: January 19th 2012 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
2
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
3
Marathon Health, Medbridge Partner to Launch Integrated Virtual MSK Care Program
4
Myasthenia Gravis–Induced Fears of Diagnosed Patients During the Pandemic
5
